A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

NCT01328626 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Interventions

DRUG: ABT-199

Sponsor

AbbVie

Collaborators

[object Object]